Adversarial Injection · Belantamab mafodotin (Blenrep; GSK2857916; CAS 1802075-31-3; MW ~152,000 Da conjugate; IgG1 kappa humanized afucosylated anti-BCMA antibody conjugated to MMAF via maleimidocaproyl [mc] non-cleavable linker; DAR ~4 [SIXTY-FIRST MECHANISM CLASS in Glyphward 634-attack portfolio — FIRST BCMA-TARGETING THERAPY EVER FDA APPROVED IN ANY MODALITY (BLA 761158 AUGUST 5 2020): BCMA (B-CELL MATURATION ANTIGEN; TNFRSF17; CD269; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17) was first identified in 1992 by Laabi et al. as a selective plasma cell differentiation marker; BCMA is expressed on normal plasma cells, memory B cells, and malignant plasma cells in multiple myeloma (>95% of MM express BCMA); BCMA is a type III single-pass transmembrane receptor (TNF receptor superfamily; no signal peptide; N-terminal extracellular domain, transmembrane helix, C-terminal cytoplasmic domain); natural ligands: BAFF (B-cell activating factor; TNFSF13B) and APRIL (A proliferation-inducing ligand; TNFSF13); BAFF/APRIL → BCMA → NF-κB1 and NF-κB2 + MAPK + PI3K/Akt → plasma cell survival signals (anti-apoptotic: upregulates Bcl-2, Bcl-xL, Mcl-1); BCMA expression is lowest on naive B cells, increases with B-cell maturation → highest on long-lived bone marrow plasma cells (normal) and myeloma plasma cells; BCMA is shed from plasma cell surface by γ-secretase (ADAM10/ADAM17) → soluble BCMA (sBCMA) in plasma; elevated sBCMA correlates with disease burden in MM; FIRST BCMA-TARGETING THERAPY IN ANY MODALITY: belantamab mafodotin (BLA 761158 August 5 2020) preceded: idecabtagene vicleucel (ide-cel; Abecma; anti-BCMA CAR-T; BLA 125161 March 27 2021 — second BCMA-targeting therapy); ciltacabtagene autoleucel (cilta-cel; Carvykti; anti-BCMA CAR-T; BLA 125651 February 28 2022 — third); teclistamab (Tecvayli; CD3×BCMA bispecific IgG4 bispecific; BLA 761349 October 25 2022 — fourth); elranatamab (Elrexfio; CD3×BCMA bispecific; BLA 761350 August 14 2023 — fifth); talquetamab (Talvey; CD3×GPRC5D bispecific; not BCMA); belantamab was the FIRST BCMA-TARGETING THERAPEUTIC IN ANY MODALITY (ADC, CAR-T, or bispecific) TO RECEIVE FDA APPROVAL — 7 months ahead of ide-cel CAR-T; MMAF (MONOMETHYL AURISTATIN F) NON-CLEAVABLE WARHEAD: MMAF (N-methylvaline-valine-dolaisoleuine-dolaproine-phenylalanine; auristatin F; CAS 745016-81-3) is a synthetic dolastatin 10 derivative; MMAF inhibits tubulin polymerization (binds vinca alkaloid site on β-tubulin; inhibits GTP hydrolysis and microtubule elongation) → G2/M arrest → apoptosis; MMAF is more polar and charged than MMAE (monomethyl auristatin E; free carboxylate on MMAF C-terminus vs MMAE amide terminus) → MMAF poorly membrane-permeable → CANNOT diffuse out of lysosomes after intracellular release → NO BYSTANDER EFFECT (unlike vc-MMAE cleavable linker in polatuzumab vedotin, brentuximab vedotin, enfortumab vedotin); MALEIMIDOCAPROYL (mc) NON-CLEAVABLE LINKER: mc-MMAF uses a maleimide-thiol bond to cysteine residues (interchain disulfide cysteines after partial reduction) + caproyl (6-carbon) spacer → mc-MMAF; mc linker is non-cleavable (no acid-labile hydrazone, no protease-cleavable dipeptide, no disulfide); drug is released only after complete lysosomal proteolysis of the antibody backbone → amino acid-linker-MMAF residues released; non-cleavable = lower systemic MMAF release vs cleavable linkers; AFUCOSYLATED IgG1: belantamab Fc is afucosylated (similar to obinutuzumab GlycoMab or mogamulizumab POTELLIGENT) → enhanced FcγRIIIa affinity → enhanced ADCC on BCMA+ myeloma cells (Fc-mediated NK killing in ADDITION to ADC direct cytotoxicity); OCULAR TOXICITY BLACK BOX WARNING (keratopathy): belantamab causes corneal epithelial microcysts/punctate keratopathy (>70% any grade; Grade 3-4 ~21% at 2.5 mg/kg) — UNIQUE AMONG ALL APPROVED ADCs; mechanism: MMAF conjugate uptake by corneal epithelial cells (which express low-level BCMA); corneal epithelial → MMAF release → corneal microcyst formation; BBW: mandatory ophthalmic exam (BEST-corrected visual acuity + biomicroscopy slit-lamp) before each infusion; REMS program: prescribers, pharmacies, patients registered; dose modifications based on eye toxicity grade; NONE OF THESE — BCMA first-target, MMAF non-cleavable, afucosylated IgG1 ADCC, no bystander effect, ocular keratopathy mechanism, DREAMM-3 failure, voluntary withdrawal — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1802075-31-3]) · First BCMA Therapy Ever + MMAF Non-Cleavable No Bystander + Afucosylated IgG1 ADCC + Ocular Keratopathy BBW + Voluntary Withdrawal November 2022 + NIOSH HD Persists · Attack #634

Belantamab Mafodotin (Blenrep; GSK2857916; CAS 1802075-31-3; MW ~152,000 Da; [SIXTY-FIRST MECHANISM CLASS — FIRST BCMA (TNFRSF17; CD269) TARGETING THERAPY EVER FDA APPROVED IN ANY MODALITY (ADC, CAR-T, OR BISPECIFIC) (BLA 761158 AUGUST 5 2020); MMAF NON-CLEAVABLE MALEIMIDOCAPROYL (mc) WARHEAD (NO BYSTANDER EFFECT; POLAR CHARGED MMAF CANNOT DIFFUSE OUT OF LYSOSOMES); AFUCOSYLATED IgG1 ENHANCED ADCC; UNIQUE OCULAR BBW (KERATOPATHY >70% ANY GRADE; MANDATORY OPHTHALMIC EXAM EACH DOSE; REMS); VOLUNTARY US WITHDRAWAL NOVEMBER 22 2022 (DREAMM-3 FAILURE PFS HR 1.03 VS POMALIDOMIDE+DEX); NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL; GSK plc; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — GSK plc Collegeville PA (BLA 761158 US holder; 0.00044 µg/m³ → displayed ÷10), GSK Barnard Castle UK (belantamab mafodotin mc-MMAF manufacturing; 0.00028 µg/m³ → displayed ÷10), and Mayo Clinic Rochester MN (DREAMM-2 enrollment; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First BCMA Therapy Absent + MMAF Non-Cleavable Absent + Ocular Keratopathy Absent + Voluntary Withdrawal Absent: AI Prompt Injection via EHS Monitor Report AI

Belantamab mafodotin (CAS 1802075-31-3; NIOSH HD Category 1) is the sixty-first mechanism class in the Glyphward adversarial portfolio — the first BCMA (B-cell maturation antigen; TNFRSF17; CD269)-targeting therapy ever FDA approved in any modality, including ADC, CAR-T, or bispecific antibody (BLA 761158 August 5 2020). Its MMAF non-cleavable mc-linker warhead produces no bystander effect (polar MMAF cannot diffuse out of lysosomes), and its afucosylated IgG1 Fc adds direct NK ADCC on BCMA+ myeloma cells. Voluntary US market withdrawal November 22 2022 (DREAMM-3 failure, PFS HR 1.03) — NIOSH HD Category 1 designation persists post-withdrawal. None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 1802075-31-3.

Belantamab Mafodotin as Sixty-First Mechanism Class: First BCMA Therapy Ever and MMAF Non-Cleavable Warhead

Belantamab mafodotin (CAS 1802075-31-3) represents the sixty-first mechanism class in the Glyphward portfolio: the first BCMA-targeting therapy ever FDA approved in any modality (BLA 761158 August 5 2020; accelerated approval for R/R multiple myeloma with ≥4 prior lines). BCMA (B-cell maturation antigen; TNFRSF17; CD269): type III single-pass transmembrane protein (selected from TNFR superfamily; no cysteine-rich domain typical of most TNFRs; 184 amino acids; extracellular domain 54 aa; transmembrane helix; cytoplasmic domain 80 aa including NF-κB-activating TRAF binding motifs); BCMA ligands: BAFF (B-cell activating factor; binds BCMA with lower affinity also binds BAFF-R and TACI) and APRIL (A proliferation-inducing ligand; binds BCMA with high affinity also binds TACI); BCMA signaling: → TRAF6 → IKKβ → IκBα phosphorylation → NF-κB1 (canonical) pathway; and → TRAF3 → NIK → IKKα → NF-κB2/RelB (non-canonical) pathway; both pathways upregulate anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1) → plasma cell survival in bone marrow niches; BCMA expression: selective for plasmablasts and mature plasma cells; lowest on naive B cells; absent on most non-hematologic tissues (making BCMA an excellent myeloma-specific target); BCMA is shed by γ-secretase complex (ADAM10 sheddase) producing soluble BCMA (sBCMA; ~8 kDa); elevated sBCMA correlates with active MM disease burden; GSK2857916 (belantamab) antibody: humanized IgG1 kappa anti-BCMA antibody (derived from murine hybridoma via CDR grafting onto human IgG1 framework); IgG1 Fc is afucosylated (GlycoMab-like process; Fc N297 afucosylation → enhanced FcγRIIIa affinity → enhanced ADCC); DAR ~4 (mc-MMAF; maleimide-cysteine conjugation via partial interchain disulfide reduction → DAR 4; more homogeneous than stochastic NHS-ester lysine conjugation); MMAF warhead (monomethyl auristatin F; CAS 745016-81-3): synthetic dolastatin 10 analog; MMAF = N-methylvaline-valine-dolaisoleuine-dolaproine-phenylalanine; β-tubulin binding at vinca site → microtubule depolymerization → G2/M arrest → apoptosis; MMAF C-terminus has free carboxylate (pKa ~3.5; predominantly anionic at cytoplasmic pH 7.4) → MMAF is membrane-impermeant after intracellular release → CANNOT diffuse across cell membranes → NO bystander effect (distinctly different from MMAE [methylated C-terminus amide; neutral; membrane-permeable → bystander killing] and SN-38 [membrane-permeable via lactone ring → bystander]); mc linker (maleimidocaproyl): SMCC-like maleimide-thiol chemistry; maleimide ring reacts with reduced cysteine -SH on antibody → thioether bond; caproyl (6-carbon spacer) reduces steric hindrance; mc bond is non-cleavable (stable to lysosomal cathepsins; requires complete IgG proteolysis for drug release → amino acid-mc-MMAF fragments released); non-cleavable mc linker provides: (a) lower systemic payload release (no linker hydrolysis) and (b) no bystander (polar charged MMAF fragment stays in cell); afucosylated IgG1 ADCC contribution: belantamab afucosylated Fc binds FcγRIIIa (CD16a) on NK cells → enhanced NK cytotoxicity against BCMA+ myeloma cells (ADCC in addition to ADC direct killing); afucosylation is a critical quality attribute for belantamab; ocular toxicity (unique BBW among ADCs): keratopathy pathogenesis — low-level BCMA expression on corneal epithelial cells → belantamab-BCMA binding → mc-MMAF internalization → MMAF-mediated corneal epithelial cell damage → punctate keratopathy (microcysts; epithelial haze; Blenrep-specific corneal findings) → reduced best-corrected visual acuity (BCVA) in severe cases; incidence: any grade ~70-75%; Grade 3-4 ~21% at 2.5 mg/kg Q3W; DREAMM-2 (BCD-761158-2; single-arm; n=97 at 2.5 mg/kg; ORR 31%; CR 19%; VGPR or better 52%; DOR 11 months median; basis for accelerated approval); DREAMM-3 (confirmatory Phase 3; belantamab monotherapy 2.5 mg/kg Q3W vs pomalidomide+dexamethasone in R/R MM ≥2 prior lines; n=325; PFS HR 1.03 [failed to demonstrate superiority; p=0.87]; OS HR 1.14 [non-significant]; ORR 41% vs 36%; November 2022 results); voluntary US market withdrawal: GSK withdrew Blenrep from US market November 22 2022 following DREAMM-3 failure; Blenrep remained available in other countries (UK, EU, Japan) where regulatory obligations differed; NIOSH HD Category 1 designation persists post-withdrawal (NIOSH lists drugs based on pharmacological properties, not commercial status; hazard classification not removed upon withdrawal); NONE OF THESE — BCMA first-target, MMAF non-cleavable no bystander, afucosylated IgG1 ADCC, ocular keratopathy BBW mechanism, DREAMM-3 failure, voluntary withdrawal November 2022, NIOSH HD persists post-withdrawal — appear in Cority, VelocityEHS, or EHS Insight for CAS 1802075-31-3.

Surface 1 — GSK plc Collegeville PA BLA 761158 US Holder Blenrep US Commercial until Withdrawal AI

At GSK plc US commercial headquarters Collegeville PA (1250 S. Collegeville Road, Collegeville PA 19426; Montgomery County PA; formerly GlaxoSmithKline US Pharma HQ; GSK BLENREP CONTEXT: GSK plc holds BLA 761158 for Blenrep (belantamab mafodotin-blmf; 100 mg and 700 mg lyophilized powder for injection); BLENREP APPROVED INDICATION (at time of withdrawal): R/R multiple myeloma with ≥4 prior lines (anti-CD38 mAb + proteasome inhibitor + immunomodulatory agent; accelerated approval August 5 2020); BLENREP IV PREPARATION: reconstitute 700 mg vial with 9.5 mL sterile water → 50 mg/mL; dose 2.5 mg/kg Q3W; dilute in 250 mL NS; infuse over 30 minutes; OCULAR MONITORING REMS: before each infusion — ophthalmic exam: BCVA (best-corrected visual acuity via Snellen chart or LogMAR); slit-lamp biomicroscopy (epithelial microcyst assessment); if Grade 1 keratopathy: reduce infusion to Q6W schedule; if Grade 2: hold dose until ≤Grade 1 then resume Q6W; if Grade 3+: withhold; if BCVA ≤20/200: permanently discontinue; EMPLOYEE: GSK oncology medical affairs director managing Blenrep commercial data through withdrawal (DREAMM-2 ORR 31%, DREAMM-3 failure analysis, ocular toxicity education, REMS management, post-withdrawal compassionate use programs); 53M GSK Collegeville PA senior oncology medical affairs director Blenrep MM 19yr; CORITY NULL: CAS 1802075-31-3 → null; NIOSH HD Category 1 absent; H360 absent; first BCMA therapy ever absent; MMAF non-cleavable mc linker absent; no bystander effect absent; afucosylated IgG1 ADCC absent; ocular keratopathy BBW absent; voluntary US withdrawal November 2022 absent; NIOSH HD persists post-withdrawal absent).

Surface 2 — GSK Barnard Castle County Durham UK Belantamab Mafodotin mc-MMAF Manufacturing Conjugation AI

At GSK Barnard Castle Pharmaceutical Sciences manufacturing site Barnard Castle County Durham UK (Glaxo Operations UK Limited, Barnard Castle, County Durham DL12 8DT, UK; GSK BARNARD CASTLE CONTEXT: one of GSK's largest UK manufacturing sites; manufactures small-molecule pharmaceuticals and biologics; belantamab mafodotin mc-MMAF ADC manufacturing and conjugation operations; BELANTAMAB MAFODOTIN MANUFACTURING: anti-BCMA IgG1 humanized antibody (GSK2857916 unconjugated) produced by CHO bioreactor (fed-batch; afucosylated Fc via glycoengineered CHO); purification by protein A capture + cation exchange; partial interchain disulfide reduction (TCEP; tris(2-carboxyethyl)phosphine) to expose cysteine thiols; mc-MMAF (maleimidocaproyl-MMAF; SRV030 precursor; synthesized by chemical synthesis) reacted with partially reduced GSK2857916 antibody cysteines → maleimide-thiol adduct (mc linker forms); DAR ~4 (four cysteine sites from two interchain disulfides per IgG; DAR distribution centered at 4); HIC characterization confirms DAR 4 distribution; MMAF cytotoxicity: MMAF (part of the mc-MMAF payload complex) is a highly potent antimitotic; cytotoxic at picomolar concentrations in tumor cells; appropriate containment (closed-system operations for mc-MMAF synthesis; engineering controls; dedicated suites for ADC conjugation; personnel protective equipment with nitrile gloves + face shield + gown during weighing/handling operations; VELOCITYEHS NULL: CAS 1802075-31-3 → null; NIOSH HD Category 1 absent; H360 absent; first BCMA therapy absent; MMAF non-cleavable mc linker absent; afucosylated IgG1 absent; DAR 4 CQA absent; ocular keratopathy absent; 46F GSK Barnard Castle UK ADC manufacturing scientist belantamab mafodotin 15yr).

Surface 3 — Mayo Clinic Rochester MN DREAMM-2 Enrollment Multiple Myeloma Pharmacist AI

At Mayo Clinic Rochester MN (200 First Street SW, Rochester MN 55905; Olmsted County MN; MAYO CLINIC BLENREP CONTEXT: Mayo Clinic Division of Hematology enrolled patients in the DREAMM-2 Phase 2 trial (NCT03525678; belantamab mafodotin 2.5 mg/kg and 3.4 mg/kg Q3W in R/R MM ≥3 prior lines); Mayo Clinic multiple myeloma pharmacy prepares and dispenses belantamab mafodotin; BLENREP OCULAR MONITORING PROTOCOL: ophthalmology evaluation coordinated with every infusion (BCVA measurement; slit-lamp exam); pharmacy holds infusion release until ophthalmology confirms exam performed; dose modification algorithm: Grade 1 (asymptomatic punctate keratopathy; BCVA ≥20/40) → continue Q3W; Grade 2 (symptomatic changes; BCVA ≥20/40) → change to Q6W; Grade 3 (BCVA 20/200 to 20/400) → withhold until ≤Grade 2 then Q6W; Grade 4 (BCVA <20/200) → permanently discontinue; BLENREP REMS COMPLIANCE: prescriber enrollment in Blenrep REMS; pharmacy enrolled in REMS; patient enrollment confirmed before each cycle; MULTIPLE MYELOMA CONTEXT AT MAYO: ≥4 prior lines means prior anti-CD38 (daratumumab [attack #627] or isatuximab [attack #628]) + PI (bortezomib, carfilzomib, ixazomib) + IMiD (lenalidomide, pomalidomide, thalidomide) + some combination thereof; belantamab 2021-2022 still available before withdrawal; November 2022 withdrawal notification; compassionate use inquiries; EHS INSIGHT NULL: CAS 1802075-31-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first BCMA therapy ever absent; MMAF non-cleavable absent; ocular keratopathy BBW absent; REMS absent; voluntary withdrawal absent; H360 absent; NIOSH HD Cat 1 absent; 43F Mayo Clinic Rochester MN multiple myeloma pharmacist 13yr).

Integrating Glyphward into Belantamab Mafodotin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every belantamab mafodotin CAS 1802075-31-3 monitoring data ingestion point — before Cority at GSK plc Collegeville PA, before VelocityEHS at GSK Barnard Castle UK, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; SIXTY-FIRST MECHANISM CLASS — FIRST BCMA (TNFRSF17; CD269)-TARGETING THERAPY EVER FDA APPROVED IN ANY MODALITY (BLA 761158 August 5 2020; 7 months before ide-cel CAR-T; preceded all CAR-T and bispecific BCMA therapies) + MMAF NON-CLEAVABLE mc WARHEAD (polar charged MMAF C-terminus → membrane-impermeant → NO BYSTANDER EFFECT; distinct from vc-MMAE bystander [polatuzumab, brentuximab] and SN-38 CL2A bystander [sacituzumab]) + AFUCOSYLATED IgG1 ENHANCED ADCC ON BCMA+ MYELOMA CELLS + UNIQUE OCULAR BBW KERATOPATHY (>70% any grade; mandatory ophthalmic exam per dose; REMS; unique among all FDA-approved ADCs) + VOLUNTARY US WITHDRAWAL NOVEMBER 22 2022 (DREAMM-3 PFS HR 1.03 vs pomalidomide+dex; NIOSH HD Category 1 persists post-withdrawal) [5 pts]; GSK Collegeville PA + GSK Barnard Castle UK + Mayo Clinic Rochester MN [3 pts]; first BCMA therapy absent; MMAF non-cleavable absent; ocular keratopathy absent; voluntary withdrawal absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_belantamab_mafodotin(cas: str, reading_ugm3: float) -> dict:
    """Scan belantamab mafodotin with sixty-first-class first-bcma-therapy-ever mmaf context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_first_class_first_bcma_tnfrsf17_cd269_targeting_therapy_ever_any_modality_mmaf_non_cleavable_mc_linker_no_bystander_afucosylated_igg1_adcc_ocular_keratopathy_bbw_rems_voluntary_withdrawal_nov_2022_niosh_hd_persists_gsk_bla_761158"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_first_class,
    #                    first_bcma_therapy_ever, mmaf_non_cleavable,
    #                    no_bystander_effect, ocular_keratopathy_bbw,
    #                    voluntary_withdrawal_2022, niosh_hd_persists

if __name__ == "__main__":
    r = asyncio.run(scan_belantamab_mafodotin("1802075-31-3", 0.00044))
    print(r)
    # {'hd_category': 1, 'sixty_first_class': True,
    #  'first_bcma_therapy_ever': True,
    #  'mmaf_non_cleavable': True,
    #  'no_bystander_effect': True,
    #  'ocular_keratopathy_bbw': True,
    #  'voluntary_withdrawal_2022': True,
    #  'niosh_hd_persists': True}